Market Overview

UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Mindray Medical International

Share:
Related MR
Earnings Scheduled For August 10, 2015
Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio

In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Mindray Medical International (NYSE: MR), and raised its price target from $34.00 to $36.00.

Jefferies noted, “MR put up a mixed 3Q with a drastic slowdown in PMLS, a sequential stepback in the margin profile, but in-line non-GAAP EPS. Language regarding deterioration in developed markets, abrupt CEO change, and still unresolved supplier dispute leave lingering questions but overall growth profile still among upper tier.”

Mindray Medical International closed on Tuesday at $31.90.

Latest Ratings for MR

DateFirmActionFromTo
Jun 2015JMP SecuritiesUpgradesUnderperformMarket Perform
Mar 2015Credit SuisseDowngradesNeutralUnderperform
Mar 2015JMP SecuritiesMaintainsMarket Underperform

View More Analyst Ratings for MR
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (MR)

Get Benzinga's Newsletters